Short Interest in Sino Biopharmaceutical (OTCMKTS:SBMFF) Declines By 28.3%

Sino Biopharmaceutical (OTCMKTS:SBMFF - Get Free Report) was the target of a significant decrease in short interest during the month of May. As of May 31st, there was short interest totalling 26,678,100 shares, a decrease of 28.3% from the May 15th total of 37,216,500 shares. Approximately 0.1% of the company's shares are sold short. Based on an average daily volume of 700 shares, the short-interest ratio is presently 38,111.6 days.

Sino Biopharmaceutical Price Performance

Sino Biopharmaceutical stock remained flat at $0.64 during mid-day trading on Friday. The business has a 50 day moving average price of $0.53 and a two-hundred day moving average price of $0.46. Sino Biopharmaceutical has a 1 year low of $0.31 and a 1 year high of $0.77.

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.